The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Which Neuroprotective Agents are Ready for Bench to Bedside Translation in the Newborn Infant?
Open accessAbstract
Neonatal encephalopathy caused by perinatal hypoxiaischemia in term newborn infants occurs in 1 to 3 per 1000 births1 and leads to high mortality and morbidity rates with life-long chronic disabilities.2,3 Although therapeutic hypothermia is a significant advance in the developed world and improves outcome,4,5 hypothermia offers just 11% reduction in risk of death or disability, from 58% to 47%. Therefore, there still is an urgent need for other treatment options. Further, there are currently no clinically established interventions that can be given antenatally to ameliorate brain injury after fetal distress. One of the major limitations to progress is what may be called “the curse of choice.” A large number of possible neuroprotective therapies have shown promise in pre-clinical studies.6,7 How should we select from them? There is no consensus at present on which drugs have a high chance of success for either antenatal or postnatal treatment. There are insufficient societal resources available to test them all. Thus, it is imperative to marshal finite resources and prioritize potential therapies for investigation. The authors believe that facilitating discussion of strategy and findings in “competing” laboratories is critical to facilitate efficient progress toward optimizing neuroprotection after hypoxia-ischemia. Few studies have examined possible interactions of medications with hypothermia and whether combination therapies augment neuroprotection. The timing of the administration of medications may be critical to optimize benefit and avoid neurotoxicity (eg, early acute treatments targeted at amelioration of the neurotoxic cascade compared with subacute treatment that can promote regeneration and repair). Intervention early on in the cascade of neural injury is likely to achieve more optimal neuroprotection8,9; however, there is frequently little warning of impending perinatal hypoxia-ischemia episodes. Sensitizing factors such as maternal pyrexia,10 maternal/fetal infection,11,12 and poor fetal growth13 are well recognized and contribute to the heterogeneity of the fetal response and outcome in neonatal encephalopathy. We include potential antenatal therapy medications in the scoring process; however, electronic fetal monitoring has a low positive predictive value (3%–18%) for identifying intrapartum asphyxia.14–18 At present, therefore, any antenatal intervention potentially involves treatment of many cases that do not need treatment in order to benefit a few at risk of brain injury. In January 2008, investigators from research institutions with a special interest in neuroprotection of the newborn appraised published evidence about medications that have been used in pre-clinical animal models, pilot clinical studies, or both as treatments for: (1) antenatal therapy for fetuses with a diagnosis of antenatal fetal distress at term; and (2) postnatal therapy of infants with moderate to severe neonatal encephalopathy. The aims of this study were to: (1) prioritize potential treatments for antenatal and postnatal therapy; and (2) provide a balanced reference for further discussions in the perinatal neuroscience community for future research and clinical translation of novel neuroprotective treatments of the newborn.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gluckman, P. D., Wyatt, J. S., Azzopardi, D., Ballard, R., Edwards, A. D., Ferriero, D. M., Polin, R. A., Robertson, C. M., Thoresen, M., Whitelaw, A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17946-x · Cited by 2,270
Self-citationUpdate of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Satomoto, M., Satoh, Y., Terui, K., Miyao, H., Takishima, K., Ito, M., & Imaki, J. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181974fa2 · Cited by 496
Jackson, T. S., Xu, A., Vita, J. A., & Keaney, J. F. (1998) · Circulation Research · doi:10.1161/01.res.83.9.916 · Cited by 400
“Control” laboratory rodents are metabolically morbid: Why it matters
Martin, B., Ji, S., Maudsley, S., & Mattson, M. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912955107 · Cited by 354
Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain
Lanté, F., Meunier, J., Guiramand, J., Maurice, T., Cavalier, M., de Jesus Ferreira, M.-C., Aimar, R., Cohen-Solal, C., Vignes, M., & Barbanel, G. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.01.027 · Cited by 140
Melatonin Promotes Oligodendroglial Maturation of Injured White Matter in Neonatal Rats
Olivier, P., Fontaine, R. H., Loron, G., Van Steenwinckel, J., Biran, V., Massonneau, V., Kaindl, A., Dalous, J., Charriaut-Marlangue, C., Aigrot, M.-S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007128 · Cited by 119
An Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Yu, L., Derrick, M., Ji, H., Silverman, R. B., Whitsett, J., Vásquez-Vivar, J., & Tan, S. (2011) · Developmental Neuroscience · doi:10.1159/000327244 · Cited by 38
Self-citation
Cited by
White matter injury in the preterm infant: pathology and mechanisms
Back, S. A. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1718-6 · Cited by 473
Self-citationSchumacher, M., Mattern, C., Ghoumari, A., Oudinet, J. P., Liere, P., Labombarda, F., Sitruk-Ware, R., De Nicola, A. F., & Guennoun, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.004 · Cited by 355
Thoresen, M., Tooley, J., Liu, X., Jary, S., Fleming, P., Luyt, K., Jain, A., Cairns, P., Harding, D., & Sabir, H. (2013) · Neonatology · doi:10.1159/000353948 · Cited by 318
Azzopardi, D., Robertson, N. J., Bainbridge, A., Cady, E., Charles-Edwards, G., Deierl, A., Fagiolo, G., Franks, N. P., Griffiths, J., Hajnal, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00347-6 · Cited by 220
Self-citationPathophysiology of glia in perinatal white matter injury
Back, S. A., & Rosenberg, P. A. (2014) · Glia · doi:10.1002/glia.22658 · Cited by 202
Self-citation
Metadata
- Authors
- Robertson, N. J., Tan, S., Groenendaal, F., van Bel, F., Juul, S. E., Bennet, L., Derrick, M., Back, S. A., Chavez Valdez, R., Northington, F., Gunn, A. J., & Mallard, C.
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 160
- Issue
- 4
- Pages
- 544-552.e4
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W2149763277
- Cited by
- 159
- References
- 10
- FWCI
- 13.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.